Answers are grounded in this paper and cite their sources.
The treatment of patients with non- Hodgkin’s lymphoma (NHL) is often the treatment of elderly patients, as most patients are older than 65 years at diagnosis. These elderly patients present particular therapeutic challenges, because they may be more frail and at greater risk of treatment-related toxicity, especially anthracycline-related cardiotoxicity, than younger patients. The following two case studies illustrate the challenges and therapeutic decision-making in managing elderly patients with an aggressive and an indolent form of lymphoma.
No takes yet. Share an insight, caveat, or question.
Luminari et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: